Study of overall survival associated with nintedanib and pirfenidone in patients with idiopathic pulmonary fibrosis: a real-life comparison

Idiopathic pulmonary fibrosis (IPF) is a rare disease with a very debilitating course for which only limited therapeutic options are available. The incidence of IPF is increasing worldwide and in Italy ranges between 7.5 and 9.3 new cases per 100 000 per year.1 It is characterized by progressive and irreversible scarring of lung tissue resulting in a decline in respiratory function and usually a fatal outcome; survival of patients with IPF is usually less than 5 years from diagnosis.2 Currently, pharmacological treatments include only two active ingredients to delay disease progression: nintedanib, a tyrosine kinase inhibitor, and pirfenidone, a molecule with anti-inflammatory and antifibrotic activities. A retrospective analysis was conducted by hospital pharmacy staff at a …

留言 (0)

沒有登入
gif